A nanotechnology based new approach for chemotherapy of Cutaneous Leishmaniasis: TIO2@AG nanoparticles - Nigella sativa oil combinations

Experimental Parasitology

Volumn 166, Issue , 2016, Pages 150-163

  Abamor, Emrah Sefik ^a   Allahverdiyev, Adil M ^a  

^a YILDIZ TECHNICAL UNIVERSITY   (Turkey)

Author keywords

Cutaneous; Leishmania; Leishmaniasis; Nanoparticles; Nanotechnology; Nigella sativa; Silver; Titanium

Indexed keywords

ANTIPARASITIC AGENT; ESSENTIAL OIL; NIGELLA SATIVA ESSENTIAL OIL; NITRIC OXIDE; SILVER DOPED TITANIUM DIOXIDE NANOPARTICLE; SILVER NANOPARTICLE; TITANIUM DIOXIDE NANOPARTICLE; UNCLASSIFIED DRUG; ANTIPROTOZOAL AGENT; CARAWAY OIL; DRUG COMBINATION; METAL NANOPARTICLE; SILVER; TITANIUM; TITANIUM DIOXIDE; VEGETABLE OIL;

AMASTIGOTE; ANIMAL CELL; APOPTOSIS; ARTICLE; BLACK CUMIN; CELL PROLIFERATION; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG EFFECT; DRUG EFFICACY; INFECTION RATE; LEISHMANIA TROPICA; MACROPHAGE CULTURE; METABOLIC REGULATION; MOUSE; NANOTECHNOLOGY; NONHUMAN; PARASITE VIRULENCE; PRIORITY JOURNAL; PROMASTIGOTE; SKIN LEISHMANIASIS; ANIMAL; CELL LINE; DRUG COMBINATION; DRUG EFFECTS; FLOW CYTOMETRY; GROWTH, DEVELOPMENT AND AGING; IC50; LEISHMANIASIS, CUTANEOUS; MACROPHAGE; METABOLISM; PARASITOLOGY; SCANNING ELECTRON MICROSCOPY; TRANSMISSION ELECTRON MICROSCOPY;

ANIMALS; ANTIPROTOZOAL AGENTS; APOPTOSIS; CELL LINE; DRUG COMBINATIONS; FLOW CYTOMETRY; INHIBITORY CONCENTRATION 50; LEISHMANIA TROPICA; LEISHMANIASIS, CUTANEOUS; MACROPHAGES; METAL NANOPARTICLES; MICE; MICROSCOPY, ELECTRON, SCANNING; MICROSCOPY, ELECTRON, TRANSMISSION; NITRIC OXIDE; PLANT OILS; SILVER; TITANIUM;

EID: 84964425407     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2016.04.008     Document Type: Article

References (59)

1. Ahmad A., Husain A., Mujeeb M., Khan S.A., Najmi A.K., Siddique N.A., Damanhouri Z.A., Anwar F. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac. J. Trop. Biomed. 2013, 3(5):337-352.
2. Ahmad Z., Laughlin T.F., Kady I.O. Thymoquinone inhibits Escherichia coli ATP synthase and cell growth. PLoS One 2015, 10(5):e0127802.
3. Allahverdiyev A.M., Kon K.V., Abamor E.S., Bagirova M., Rafailovich M. Coping with antibiotic resistance: combining nanoparticles with antibiotics and other antimicrobial agents. Expert Rev. Anti Infect. Ther. 2011, 9(11):1035-1052.
4. Allahverdiyev A.M., Abamor E.S., Bagirova M., Rafailovich M. Antimicrobial effects of TiO(2) and Ag(2)O nanoparticles against drug-resistant bacteria and leishmanial parasites. Future Microbiol. 2011, 6(8):933-940.
5. Allahverdiyev A.M., Abamor E.S., Bagirova M., Ustundag C.B., Kaya C., Kaya F., Rafailovich M. Antileishmanial effect of silver nanoparticles and their enhanced antiparasitic activity under ultraviolet light. Int. J. Nanomedicine 2011, 6:2705-2714.
6. Allahverdiyev A.M., Abamor E.S., Bagirova M., Baydar S.Y., Ates S.C., Kaya F., Kaya C., Rafailovich M. Investigation of antileishmanial activities of Tio2@Ag nanoparticles on biological properties of L. tropica and L. infantum parasites, in vitro. Exp. Parasitol. 2013, 135(1):55-63.
7. Bakathir H.A., Abbas N.A. Detection of the antibacterial effect of Nigella sativa ground seeds with water. Afr. J. Tradit. Compl. Altern. Med. 2011, 8:159-164.
8. Banjara M.R. Combination therapy for visceral leishmaniasis. Int. J. Infect. Microbiol. 2013, 2(2):32-33.
9. Bassetti M., Righi E. New antibiotics and antimicrobial combination therapy for the treatment of gram-negative bacterial infections. Curr. Opin. Crit. Care 2015, 21(5):402-411.
10. Besinis A., De Peralta T., Handy R.D. The antibacterial effects of silver, titanium dioxide and silica dioxide nanoparticles compared to the dental disinfectant chlorhexidine on Streptococcus mutans using a suite of bioassays. Nanotoxicology 2014, 8(1):1-16.
11. Beyth N., Houri-Haddad Y., Domb A., Khan W., Hazan R. Alternative antimicrobial approach: nano-antimicrobial materials. Evid. Based Complement. Alternat. Med. 2015, 2015:246012.
12. Bhattacharjee A., Majumder S., Majumdar S.B., Choudhuri S.K., Roy S., Majumdar S. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis. Int. J. Antimicrob. Agents 2015, 45(3):268-277.
13. Bita A., Rosu A.F., Calina D., Rosu L., Zlatian O., Dindere C., et al. An alternative treatment for Candida infections with Nigella sativa extracts. Eur. J. Hosp. Pharm. 2012, 19:162.
14. de Menezes J.P., Guedes C.E., Petersen A.L., Fraga D.B., Veras P.S. Advances in development of new treatment for leishmaniasis. Biomed. Res. Int. 2015, 2015:815023.
15. Dereure J., Vanwambeke S.O., Malé P., Martinez S., Pratlong F., Balard Y., Dedet J.P. The potential effects of global warming on changes in canine leishmaniasis in a focus outside the classical area of the disease in southern France. Vector Borne Zoonotic Dis. 2009, 9(6):687-694.
16. Desjeux P. Leishmaniasis: current situation and new perspectives. Comp. Immunol. Microbiol. Infect. Dis. 2004, 27(5):305-318.
17. Dilika F., Bremner P.D., Meyer J.J. Antibacterial activity of linoleic and oleic acids isolated from Helichrysum pedunculatum: a plant used during circumcision rites. Fitoterapia 2000, 71(4):450-452.
18. Dizaj S.M., Lotfipour F., Barzegar-Jalali M., Zarrintan M.H., Adibkia K. Antimicrobial activity of the metals and metal oxide nanoparticles. Mater. Sci. Eng. C Mater Biol. Appl. 2014, 44:278-284.
19. Fischbach M.A. Combination therapies for combating antimicrobial resistance. Curr. Opin. Microbiol. 2011, 14(5):519-523.
20. Forouzanfar F., Bazzaz B.S., Hosseinzadeh H. Black cumin (Nigella sativa) and its constituent (thymoquinone): a review on antimicrobial effects. Iran. J. Basic Med. Sci. 2014, 17(12):929-938.
21. Franci G., Falanga A., Galdiero S., Palomba L., Rai M., Morelli G., Galdiero M. Silver nanoparticles as potential antibacterial agents. Molecules 2015, 20(5):8856-8874.
22. Freitas-Junior L.H., Chatelain E., Kim H.A., Siqueira-Neto J.L. Visceral leishmaniasis treatment: what do we have, what do we need and how to deliver it?. Int. J. Parasitol. Drugs Drug Resist. 2012, 2:11-19.
23. González C., Wang O., Strutz S.E., González-Salazar C., Sánchez-Cordero V., Sarkar S. Climate change and risk of leishmaniasis in north america: predictions from ecological niche models of vector and reservoir species. PLoS Negl. Trop. Dis. 2010, 4(1):e585.
24. Gupta K., Singh R.P., Pandey A., Pandey A. Photocatalytic antibacterial performance of TiO2 and Ag-doped TiO2 against S. aureus, P. aeruginosa and E.coli. Beilstein J. Nanotechnol. 2013, 4:345-351.
25. Halawani E. Antibacterial activity of thymo-quinone and thymohydroquinone of Nigella sativa L. and their interaction with some antibiotics. Adv. Biol. Res. 2009, 3:148-152.
26. Hannan A., Saleem S., Chaudhary S., Barka M., Arshad M.U. Anti-bacterial activity of Nigella sativaagainst clinicalisolates of methicillin resistant Staphylococcus aureus. J. Ayub Med. Coll. Abbottabad 2008, 20(3):72-74.
27. Jesline A., John N.P., Narayanan P.M., Vani C., Murugan S. Antimicrobial activity of zinc and titanium dioxide nanoparticles against biofilm-producing methicillin-resistant Staphylococcus aureus. Appl. Nanosci. 2015, 5(2):157-162.
28. Kato K.C., Morais-Teixeira E., Reis P.G., Silva-Barcellos N.M., Salaün P., Campos P.P., Dias Corrêa-Junior J., Rabello A., Demicheli C., Frézard F. Hepatotoxicity of pentavalent antimonial drug: possible role of residual Sb(III) and protective effect of ascorbic acid. Antimicrob. Agents Chemother. 2014, 58(1):481-488.
29. Kedziora A., Strek W., Kepinski L., Bugla-Ploskonska G., Doroszkiewicz W. Synthesis and antibacterial activity of novel titanium dioxide doped with silver. J. Sol-Gel Sci. Technol. 2012, 62(1):79-86.
30. Kumar R., Engwerda C. Vaccines to prevent leishmaniasis. Clin. Transl. Immunol. 2014, 3(3):e13.
31. Kumar R., Bumb R.A., Ansari N.A., Mehta R.D., Salotra P. Cutaneous leishmaniasis caused by Leishmania tropica in Bikaner, India: parasite identification and characterization using molecular and immunologic tools. Am. J. Trop. Med. Hyg. 2007, 76(5):896-901.
32. Machado P.R., Lessa H., Lessa M., Guimarães L.H., Bang H., Ho J.L., Carvalho E.M. Oral pentoxifylline combined with pentavalent antimony: a randomized trial for mucosal leishmaniasis. Clin. Infect. Dis. 2007, 44(6):788-793.
33. Mahmoud S.S., Torchilin V.P. Hormetic/cytotoxic effects of Nigella sativa seed alcoholic and aqueous extracts on MCF-7 breast cancer cells alone or in combination with doxorubicin. Cell Biochem. Biophys. 2012, 25(7):1392-1398.
34. Mahmoud M.R., El-Abhar H.S., Saleh S. The effect of Nigella sativa oil against the liver damage induced by Schistosoma mansoni infection in mice. J. Ethnopharmacol. 2002, 79(1):1-11.
35. Mahmoudvand H., Tavakoli R., Sharififar F., Minaie K., Ezatpour B., Jahanbakhsh S., Sharifi I. Leishmanicidal and cytotoxic activities of Nigella sativa and its active principle, thymoquinone. Pharm. Biol. 2015, 53(7):1052-1057.
36. Mouton J.W. Combination therapy as a tool to prevent emergence of bacterial resistance. Infection 1999, 2:24-28.
37. Nathan C., Cunningham-Bussel A. Beyond oxidative stress: an immunologist's guide to reactive oxygen species. Nat. Rev. Immunol. 2013, 13(5):349-361.
38. Pan X., Redding J.E., Wiley P.A., Wen L., McConnell J.S., Zhang B. Mutagenicity evaluation of metal oxide nanoparticles by the bacterial reverse mutation assay. Chemosphere 2010, 79(1):113-116.
39. Parsons J.B., Yao J., Frank M.W., Jackson P., Rock C.O. Membrane disruption by antimicrobial fatty acids releases low-molecular-weight proteins from Staphylococcus aureus. J. Bacteriol. 2012, 194(19):5294-5304.
40. Pastor J., García M., Steinbauer S., Setzer W.N., Scull R., Gille L., Monzote L. Combinations of ascaridole, carvacrol, and caryophyllene oxide against Leishmania. Acta Trop. 2015, 145:31-38.
41. Pelgrift R.Y., Friedman A.J. Nanotechnology as a therapeutic tool to combat microbial resistance. Adv. Drug Deliv. Rev. 2013, 65:1803-1815.
42. Prados J., Melguizo C., Perazzoli G., Cabeza L., Carrasco E., Oliver J., Jiménez-Luna C., Leiva M.C., Ortiz R., Álvarez P.J., Aranega A. Application of nanotechnology in the treatment and diagnosis of gastrointestinal cancers: review of recent patents. Recent Pat. Anticancer Drug Discov. 2014, 9(1):21-34.
43. Pritchard J.R., Bruno P.M., Gilbert L.A., Capron K.L., Lauffenburger D.A., Hemann M.T. Defining principles of combination drug mechanisms of action. Proc. Natl. Acad. Sci. U. S. A. 2013, 110(2):170-179.
44. Qasim M., Lim D.J., Park H., Na D. Nanotechnology for diagnosis and treatment of infectious diseases. J. Nanosci. Nanotechnol. 2014, 14(10):7374-7387.
45. Rojas R., Valderrama L., Valderrama M., Varona M.X., Ouellette M., Saravia N.G. Resistance to antimony and treatment failure in human Leishmania (Viannia) infection. J. Infect. Dis. 2006, 193(10):1375-1383.
46. Salam N., Al-Shaqha W.M., Azzi A. Leishmaniasis in the middle East: incidence and epidemiology. PLoS Negl. Trop. Dis. 2014, 8(10):e3208.
47. Salem E.M., Yar T., Bamosa A.O., Al-Quorain A., Yasawy M.I., Alsulaiman R.M., et al. Comparative study of Nigella sativa and triple therapy in eradication of Helicobacter Pylori in patients with non-ulcer dyspepsia. Saudi J. Gastroenterol. 2010, 16(3):207-214.
48. Salim L.Z., Mohan S., Othman R., Abdelwahab S.I., Kamalidehghan B., Sheikh B.Y., Ibrahim M.Y. Thymoquinone induces mitochondria-mediated apoptosis in acute lymphoblastic leukaemia in vitro. Molecules 2013, 18(9):11219-11240.
49. Saroufim M., Charafeddine K., Issa G., Khalifeh H., Habib R.H., Berry A., Ghosn N., Rady A., Khalifeh I. Ongoing epidemic of cutaneous leishmaniasis among Syrian refugees. Leban. Emerg. Infect. Dis. 2014, 20(10):1712-1715.
50. Singh S., Das S.S., Singh G., Schuff C., de Lampasona M.P., Catalán C.A. Composition, in vitro antioxidant and antimicrobial activities of essential oil and oleoresins obtained from black cumin seeds (Nigella sativa L.). Biomed. Res. Int. 2014, 2014:918209.
51. Sundar S., Rai M., Chakravarty J., Agarwal D., Agrawal N., Vaillant M., Olliaro P., Murray H.W. New treatment approach in Indian visceral leishmaniasis: single-dose liposomal amphotericin B followed by short-course oral miltefosine. Clin. Infect. Dis. 2008, 47(8):1000-1006.
52. Sundar S., Singh A., Singh O.P. Strategies to overcome antileishmanial drugs unresponsiveness. J. Trop. Med. 2014, 2014:646932.
53. Swain P., Nayak S.K., Sasmal A., Behera T., Barik S.K., Swain S.K., Mishra S.S., Sen A.K., Das J.K., Jayasankar P. Antimicrobial activity of metal based nanoparticles against microbes associated with diseases in aquaculture. World J. Microbiol. Biotechnol. 2014, 30(9):2491-2502.
54. Tamma P.D., Cosgrove S.E., Maragakis L.L. Combination therapy for treatment of infections with gram-negative bacteria. Clin. Microbiol. Rev. 2012, 25(3):450-470.
55. Toews M.L., Bylund D.B. Pharmacologic principles for combination therapy. Proc. Am. Thorac. Soc. 2005, 2(4):282-289.
56. van Griensven J., Balasegaram M., Meheus F., Alvar J., Lynen L., Boelaert M. Combination therapy for visceral leishmaniasis. Lancet Infect. Dis. 2010, 10(3):184-194.
57. Worthington R.J., Melander C. Combination approaches to combat multidrug-resistant bacteria. Trends Biotechnol. 2013, 31(3):177-184.
58. Yun H., Kim J.D., Choi H.C., Lee C.W. Antibacterial activity of CNT-Ag and GO-Ag nanocomposites against gram-negative and gram-positive bacteria. Bull. Korean Chem. Soc. 2013, 34:3261.
59. Zheng C.J., Yoo J.S., Lee T.G., Cho H.Y., Kim Y.H., Kim W.G. Fatty acid synthesis is a target for antibacterial activity of unsaturated fatty acids. FEBS Lett. 2005, 579(23):5157-5162.